Amerikanische Gesellschaft für Hirudotherapie

Hirudin ameliorates myocardial ischemia-reperfusion injury in a rat model of hemorrhagic shock and resuscitation: roles of NLRP3-signaling pathway

Basic science / preclinical published in Mol Cell Biochem (2023)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Speichel-PharmakologieArzneimittelentwicklungBai Y et al. · Molecular and cellular biochemistry, 2023

Abstract

Severe hemorrhage shock and resuscitation (HSR) has been reported to induce myocardial ischemia-reperfusion injury (MIRI), resulting in a poor prognosis. Hirudin, an effective thrombin inhibitor, can offer protection against MIRI. This study aimed to determine if hirudin administration ameliorates HSR-induced MIRI and the underlying mechanism. A rat model of HSR was established by bleeding rats to a mean arterial blood pressure of 30-35 mmHg for 45 min and then resuscitating them with all the shed blood through the left femoral vein. After HSR, 1 mg/kg of hirudin was administrated immediately. At 24 h after HSR, the cardiac injury was assessed using serum CK-MB, cTnT, hematoxylin-eosin (HE) staining, echocardiography, M1-polarized macrophages, and pyroptosis-associated factors, including cleaved caspase-1, Gasdermin D (GSDMD) N-terminal, IL-1β, and IL-18 were measured by immunofluorescence and western blot assays. Nigericin, a unique agonist, was utilized to evaluate the responsibilities of NLRP3 signaling. Under the HSR condition, rats exhibited a significant increase in myocardial injury score, an elevation of serum cTnT, CK-MB levels, an aggrandization of M1-polarized macrophages, an upregulation of pyroptosis-associated factors, including cleaved caspase-1, GSDMD N-terminal, IL-1β, and IL-18, but a significant decrease in left ventricular ejection fraction (EF%) and a reduction of left ventricular fractional shortening (FS%), while hirudin administration partially restored the changes. However, the NLRP3 agonist nigericin reversed the cardioprotective effects of hirudin. We determined the cardioprotective effects of hirudin against HSR-induced MIRI. The mechanism may involve the inhibition of NLRP3-induced pyroptosis.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsRatsAnimalsMyocardial Reperfusion InjuryNLR Family, Pyrin Domain-Containing 3 ProteinInterleukin-18HirudinsShock, HemorrhagicStroke VolumeNigericinVentricular Function, LeftCaspase 1Signal Transduction

Zusammenfassung

Rat model of hemorrhagic shock + resuscitation shows hirudin (1 mg/kg) ameliorates myocardial ischemia-reperfusion injury via inhibition of NLRP3-induced pyroptosis. Restores left ventricular function and reduces M1-macrophage polarization.

Warum dies für die Hirudotherapie relevant ist

This study investigated whether hirudin (1 mg/kg), described as an effective thrombin inhibitor, ameliorates myocardial ischemia-reperfusion injury in a rat model of hemorrhagic shock and resuscitation (HSR). Hirudin partially restored left ventricular function, reduced serum CK-MB and cTnT, decreased M1-polarized macrophages and pyroptosis-associated factors (cleaved caspase-1, GSDMD N-terminal, IL-1β, IL-18), and the NLRP3 agonist nigericin reversed these cardioprotective effects, suggesting the mechanism involves inhibition of NLRP3-induced pyroptosis. The abstract does not describe hirudin as leech-derived, nor does it specify the route of administration. This is a single-dose animal study with no human data, and no leech application is involved; the leech connection rests solely on hirudin being a well-known thrombin inhibitor.

Zitation

Hirudin ameliorates myocardial ischemia-reperfusion injury in a rat model of hemorrhagic shock and resuscitation: roles of NLRP3-signaling pathway.

Bai Y et al. · Molecular and cellular biochemistry, 2023

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.